More Individualized Care: Assessment and Recovery Through Engagement

N/AActive Not RecruitingNCT05122676

Kaiser Permanente805 enrolled

Overview

The MI-CARE trial tests 12 months of telephone-based nurse care management for patients with depressive symptoms who take or have taken opioids at some time. The study tests whether offering nurse support to the patient and their primary care team that addresses these things and related issues can improve patients' health and well-being. Eligible subjects are identified automatically using health system data and randomly assigned 50:50 to either a no-contact usual care arm or to the arm offered the MI-CARE program.

The MI-CARE trial is a randomized encouragement trial that will test whether offering a primary care-based collaborative care (CC) model can increase opioid use disorder (OUD) treatment and improve depression outcomes among patients with: 1. recent electronic health record (EHR) documentation of depressive symptoms, and 2. evidence of OUD documented in the prior year. The study objective is to evaluate the effectiveness of offering eligible primary care patients the MI-CARE CC program for up to 12 months when compared to usual primary care. Among all eligible primary care patients, MI-CARE and usual primary care will be compared to assess the following outcomes: * Aim 1: Days of OUD medication treatment (buprenorphine) * Aim 2: Improvement of depression symptoms. * Aim 3 (intervention arm only): Examining a) implementation using mixed-methods formative evaluation including reach, adoption, and implementation fidelity, and b) nurse care manager time needed to support the MICARE intervention. The MI-CARE CC intervention is offered by a nurse care manager (NCM) and delivered by telephone (or video) visits to consenting patients. The intervention is designed to support "whole health" by engaging patients in medication treatment for OUD and depression, reducing depressive symptoms, and addressing common comorbid conditions that complicate OUD and depression (e.g., anxiety, pain, sleep, and other mental health and substance use disorders). The Collaborative Care Model was originally designed to improve mental health outcomes in primary care and includes 5 essential elements. The CC intervention tested in the MI-CARE trial will include each of these elements: population-based care, patient-centered team care, evidence-based care, measurement-based treatment to target, and accountable care. The MI-CARE program begins with NCM care focused on PCP and patient engagement: * Care team engagement - In addition to engaging the patient, the engagement process is designed to build the relationship between the NCM and the primary care team. Prior to a patient's first outreach call, the NCM informs the PCP that their patient was selected for the CC program and offers to have an initial brief (optional) call about the program with the care team. The NCM may also reach out to engage with specialty mental health providers who are working closely with the patient. If the patient does not have an established PCP, the NCM will offer to work with the patient to establish a PCP within the healthcare system. Additionally, each site's collaborative care consultants will message PCPs in their health plan when a given PCP's patient consents to participate in the MICARE intervention. These messages are to inform the PCP of the support the CC consultants provide each NCM in the management of consented patients to the intervention (including that the CC consultant's role may include various recommendations regarding patient care). * Patient engagement - This begins with a short series of "engagement" sessions to develop a relationship with the patient. Engagement sessions focus on eliciting a patient's health narrative, including current symptoms, and exploring the patient's (general) health goals, priorities, and preferences. Prior to the first engagement call the NCM reviews the patient's chart to obtain current treatment(s) for depression, OUD and related conditions. The NCM will build rapport by learning about patients' lives, how they are impacted by their health, eliciting the patients' thoughts on symptoms reported, and exploring how the program might help them. Motivational interviewing and shared decision-making techniques are used to elicit patient goals and priorities. Beginning with engagement and throughout the follow up period, the NCM will use common elements of two evidence-based core behavioral approaches: * Motivational interviewing (MI) skills to elicit ambivalence and move patients toward wanting to improve OUD, depression or other related conditions; and * Behavioral activation (BA) to help participants build skills to increase positive adaptive experiences in their day-to-day lives and support broader treatment gains.

Interventions

More Individualized Care: Assessment and Recovery through Engagement (MI-CARE)BEHAVIORAL

This study evaluates whether offering nurse collaborative care management for 12 months by telephone or video can improve depression-related symptoms, increase access to evidence-based medication treatment for opioid use problems, as well as decreasing adverse health events. Participants randomized to the nurse support arm can work with the nurse at no cost for up to 12 months via phone or video visits. The nurse asks questions about stress, mood, worry, pain, sleep, and medication and substance use; participants choose what to focus on. The nurse meets weekly with clinical consultants who may recommend treatment options, tailored to the patient. The participant and their regular provider(s) can discuss the options and decide which to try. The nurse and primary care provider can then help the patient access selected options. The nurse can also offer behavioral activation to help build skills to increase day-to-day positive adaptive experiences and support broader treatment gains.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

INCLUSION CRITERIA Eligible patients must meet all 4 criteria: 1. ≥1 in person or virtual encounter in a primary care setting in the 365 days prior to the data extraction date (pull date); 2. Age ≥18 years at the pull date; 3. ≥1 PHQ-9 depression screening score of ≥10 within the 7 days prior to the pull date. 4. Evidence of potential OUD in the 365 days prior to and including the date of the qualifying PHQ-9 score. Any 1 of the following qualifies as evidence of potential OUD: 1. ≥1 active OUD ICD-10 diagnosis code in any setting except labs; 2. ≥1 prescription (orders or dispensed) for buprenorphine (oral formulations indicated for OUD, extended release injectable, and implant); 3. ≥1 procedure code for buprenorphine (oral formulations indicated for OUD, extended release injectable, and implant); 4. ≥1 ICD-10 codes for opioid overdose; 5. ≥1 OUD ICD-10 code, including remission, and prescription (orders or dispensed) or procedure code for injectable naltrexone. EXCLUSION CRITERIA Patients are ineligible who meet any of the criteria below: 1. The only indication of OUD or only PHQ available to determine eligibility came from data protected under 42 CFR Part 2; 2. The patient has already been randomized to the trial or was outreached in the pilot study (including outreach to the primary care provider only); 3. English interpreter required (per health system records). 4. Any one of the following conditions in the 2 years prior to and including the date of the qualifying PHQ: 1. Alzheimer's disease or dementia diagnosis, or medication to treat Alzheimer's or dementia. 2. Severe cognitive limitations. 5. Current active treatment for cancer with chemotherapy or radiation therapy in the past 3 months (not including non-melanoma skin cancers). 6. Previously requested to not participate in research studies at the health system; 7. Documentation of hospice care in the 2 years prior to and including the date of the qualifying PHQ score; 8. Patient is actively being outreached for (or is participating in) depression care management (Kaiser Permanente Washington only)

Outcomes

Primary Outcomes

Days of buprenorphine medication treatment for opioid use disorder (OUD)

A continuous measure of days of OUD treatment with buprenorphine in the 365 days after randomization from secondary electronic data sources.

Time frame: days 1-365 after randomization

Secondary Outcomes

Change in depressive symptoms

Change in depressive symptoms from the study qualifying Patient Health Questionnaire (PHQ) score to follow-up PHQ score documented as part of routine clinical care 3-13. months later from secondary electronic data sources. The 9-item Patient Health Questionnaire (PHQ9) has a minimum score of 0 and a maximum score of 27. the 2-item Patient Health Questionnaire (PHQ2) has a minimum score of 0 and a maximum score of 6. An increasing PHQ score indicates an increase in depressive symptoms.

Time frame: 3-13 months after randomization